… Osteoporosis Foundation (IOF) has comprehensively updated our understanding of the
burden of disease consequent to osteoporosis … The Scorecard for Osteoporosis in Europe thus …

… cause of osteoporosis. The women after menopause are more prone to develop osteoporosis,
… Osteoporosis is most commonly associated with loss of gonadal functions in menopause …

… of purinergic receptor modulators, we can conclude that a new generation of osteoporosis
treatments is in on the horizon. These future therapeutics will hopefully bring improvements …

… Bone turnover biomarker detection may be useful in monitoring osteoporosis treatment and
assessing fracture risk but not for diagnosis of osteoporosis. Management of osteoporosis …

… Regarding age-related osteoporosis, senescent cells accumulate in bone with aging both
in mice and humans (32). Elimination of senescent cells from p16 Ink4a -INK-ATTAC mice led …

… This study was a post hoc analysis of the HORIZON Pivotal Fracture Trial evaluating the …
women with osteoporosis receiving either zoledronic acid or placebo from the HORIZON Pivotal …

… -line anti-osteoporosis therapy; the new concept of ‘very high fracture risk’ which should
prompt consideration of use of parenteral anti-osteoporosis therapy; new guidance regarding …

… Patient concerns about rare side effects of osteoporosis medicines and the perception of …
osteoporosis treatment. This chapter will start by discussing the need to treat in osteoporosis, …

… osteoporosis … new drugs intended to treat osteoporosis. At the same time, basic and clinical
advances in research have underlined the necessity to develop new technologies and new …

… In an osteoporosis RCT, it was noted that there was substantial radiographic improvement
… In 2014, the drug was restricted for its primary indication of osteoporosis, due to safety …